Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: Importance of specificity of endothelial target

Expert Review of Clinical Immunology

Volumn 10, Issue 7, 2014, Pages 885-895

  Allocca, Mariangela ^a   Fiorino, Gionata ^a   Vermeire, Severine ^b   Reinisch, Walter ^c   Cataldi, Fabio ^d   Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF VIENNA   (Austria)

^d PFIZER INC   (United States)

Author keywords

biological therapy; CAM; Crohn's disease; inflammatory bowel disease; integrins; monoclonal antibody; pathogenesis; ulcerative colitis

Indexed keywords

ABRILUMAB; CHEMOKINE; ETROLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTEGRIN; INTEGRIN RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PF 00547659; SELECTIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB;

CELL COMMUNICATION; CELL MIGRATION; CROHN DISEASE; ENDOTHELIUM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MUCOSA; LEUKOCYTE; LYMPHOCYTE; LYMPHOCYTE HOMING; MOLECULE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ULCERATIVE COLITIS; CYTOLOGY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; PATHOPHYSIOLOGY;

DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTES;

EID: 84902662355     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.917962     Document Type: Review

References (114)

1. Danese S, Fiocchi C. Ulcerative. colitis. N Engl J Med 2011;365(18):1713-25
2. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17(6): 1415-22
3. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369(9573):1627-40
4. Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010; 45(6):571-83
5. Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006;12(1):9-15
6. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12(5):382-8
7. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25: 821-52
8. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011;140(6):1768-75
9. Monteleone I, Vavassori P, Biancone L, et al. Immunoregulation in the gut: success and failures in human disease. Gut 2002; 50(Suppl 3):III60-4
10. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113(10):1490-7
11. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011;60(9):1178-81
12. Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2012;18(9):1641-6
13. Danese S, Semeraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Dis 2005;37(11): 811-18
14. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69(1):11-25
15. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804
16. Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol 2008;29(11): 555-64
17. Baaten BJ, Cooper AM, Swain SL, Bradley LM. Location, location, location: the impact of migratory heterogeneity on T cell function. Front Immunol 2013;4:311
18. Haddad W, Cooper CJ, Zhang Z, et al. P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J Exp Med 2003;198(3):369-77
19. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003;424(6944):88-93
20. Iwata M, Hirakiyama A, Eshima Y, et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004;21(4): 527-38
21. Wang S, Villablanca EJ, De Calisto J, et al. MyD88-dependent TLR1/2 signals educate dendritic cells with gut-specific imprinting properties. J Immunol 2011;187(1): 141-50
22. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003;9(6): 263-8
23. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011;118(26):6743-51
24. Cambien B, Wagner DD. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med 2004;10(4): 179-86
25. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996;88(9):3259-87
26. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 2002;14(5):581-6
27. Sako D, Chang XJ, Barone KM, et al. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell 1993;75(6):1179-86
28. Rivera-Nieves J, Burcin TL, Olson TS, et al. Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med 2006;203(4):907-17
29. Katayama Y, Hidalgo A, Chang J, et al. CD44 is a physiological E-selectin ligand on neutrophils. J Exp Med 2005;201(8):1183-9
30. Hidalgo A, Peired AJ, Wild MK, et al. Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity 2007;26(4):477-89
31. Kotovuori P, Tontti E, Pigott R, et al. The vascular E-selectin binds to the leukocyte integrins CD11/CD18. Glycobiology 1993; 3(2):131-6
32. Steegmaier M, Levinovitz A, Isenmann S, et al. The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 1995;373(6515):615-20
33. Dimitroff CJ, Lee JY, Rafii S, et al. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001;153(6):1277-86
34. Fuhlbrigge RC, King SL, Sackstein R, Kupper TS. CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006; 107(4):1421-6
35. Lasky LA, Singer MS, Dowbenko D, et al. An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell 1992;69(6): 927-38
36. Butcher EC, Williams M, Youngman K, et al. Lymphocyte trafficking and regional immunity. Adv Immunol 1999;72:209-53
37. Berg EL, McEvoy LM, Berlin C, et al. L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature 1993;366(6456): 695-8
38. Sikorski EE, Hallmann R, Berg EL, Butcher EC. The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1. J Immunol 1993;151(10):5239-50
39. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151(1): 97-110
40. Vestweber D. Regulation of endothelial cell contacts during leukocyte extravasation. Curr Opin Cell Biol 2002;14(5):587-93
41. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7(9):678-89
42. Zarbock A, Muller H, Kuwano Y, Ley K. PSGL-1-dependent myeloid leukocyte activation. J Leukoc Biol 2009;86(5): 1119-24
43. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001;305(3):285-98
44. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110(6): 673-87
45. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010;339(1): 269-80
46. Bouvard D, Pouwels J, De Franceschi N, Ivaska J. Integrin inactivators: balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol 2013;14(7):430-42
47. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 1987;51(5):813-19
48. Ben-Horin S, Bank I. The role of very late antigen-1 in immune-mediated inflammation. Clin Immunol 2004;113(2): 119-29
49. Hu MC, Crowe DT, Weissman IL, Holzmann B. Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing. Proc Natl Acad Sci USA 1992; 89(17):8254-8
50. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990;60(4):577-84
51. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74(1):185-95
52. Strauch UG, Lifka A, Gosslar U, et al. Distinct binding specificities of integrins alpha 4 beta 7 (LPAM-1), alpha 4 beta 1 (VLA-4), and alpha IEL beta 7. Int Immunol 1994;6(2):263-75
53. Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 1993; 150(8 Pt 1):3459-70
54. Karecla PI, Bowden SJ, Green SJ, Kilshaw PJ. Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). Eur J Immunol 1995;25(3):852-6
55. Schon MP, Arya A, Murphy EA, et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD 103)-deficient mice. J Immunol 1999; 162(11):6641-9
56. Elewaut D, Van Damme N, De Keyser F, et al. Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastroenterol Belg 1998;61(3):288-94
57. Oshitani N, Watanabe K, Maeda K, et al. Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD103 with epithelial adhesion molecules in inflammatory bowel disease. Int J Mol Med 2003;12(5):715-19
58. Ludviksson BR, Strober W, Nishikomori R, et al. Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/-mice. J Immunol 1999;162(8):4975-82
59. Schneider MR, Dahlhoff M, Horst D, et al. A key role for E-cadherin in intestinal homeostasis and Paneth cell maturation. PLoS One 2010;5(12):e14325
60. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270(5239):1203-7
61. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000; 275(29):21785-8
62. Staunton DE, Dustin ML, Springer TA. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989;339(6219):61-4
63. Briscoe DM, Cotran RS, Pober JS. Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. Correlation with CD3+ T cell infiltration. J Immunol 1992;149(9):2954-60
64. Fong S, Jones S, Renz ME, et al. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Its binding motif for alpha 4 beta 7 and role in experimental colitis. Immunol Res 1997;16(3):299-311
65. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10(3):387-98
66. Lawrence MB, Kansas GS, Kunkel EJ, Ley K. Threshold levels of fluid shear promote leukocyte adhesion through selectins (CD62L, P, E). J Cell Biol 1997; 136(3):717-27
67. Ley K. Arrest chemokines. Microcirculation 2003;10(3-4):289-95
68. Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol 2013; 55(1):49-58
69. Berlin C, Bargatze RF, Campbell JJ, et al. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995;80(3):413-22
70. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354(6): 610-21
71. Shamri R, Grabovsky V, Gauguet JM, et al. Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. Nat Immunol 2005;6(5):497-506
72. Wallace JL, Higa A, McKnight GW, MacIntyre DE. Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence. Inflammation 1992;16(4):343-54
73. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 1993;92(1):372-80
74. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111(5):1373-80
75. Gong Y, Barbay JK, Dyatkin AB, et al. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists. J Med Chem 2006;49(11): 3402-11
76. Kato S, Hokari R, Matsuzaki K, et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther 2000;295(1):183-9
77. Stopfer P, Obermeier F, Dunger N, et al. Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis. Clin Exp Immunol 2004;136(1):21-9
78. Shigematsu T, Specian RD, Wolf RE, et al. MAdCAM mediates lymphocyte-endothelial cell adhesion in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2001;281(5):G1309-15
79. Farkas S, Hornung M, Sattler C, et al. Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis 2006;21(1):71-8
80. Apostolaki M, Manoloukos M, Roulis M, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 2008; 134(7):2025-35
81. Rivera-Nieves J, Olson T, Bamias G, et al. L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J Immunol 2005;174(4):2343-52
82. Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001;121(6):1428-36
83. Panes J, Aceituno M, Gil F, et al. Efficacy of an inhibitor of adhesion molecule expression (GI270384X) in the treatment of experimental colitis. Am J Physiol Gastrointest Liver Physiol 2007;293(4): G739-48
84. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25
85. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132(5): 1672-83
86. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16(4):699-705
87. Maginnis MS, Atwood WJ. JC virus: an oncogenic virus in animals and humans? Semin Cancer Biol 2009;19(4):261-9
88. Delbue S, Branchetti E, Boldorini R, et al. Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. J Med Virol 2008;80(12):2147-52
89. Perez-Liz G, Del Valle L, Gentilella A, et al. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 2008;64(4):379-87
90. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354(9):924-33
91. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366(20):1870-80
92. Lysandropoulos AP, Du Pasquier RA. Demyelination as a complication of new immunomodulatory treatments. Curr Opin Neurol 2010;23(3):226-33
93. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330(3):864-75
94. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352(24):2499-507
95. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6(12):1370-7
96. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18(8):1470-9
97. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699-710
98. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369(8):711-21
99. Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 2013; 264(1-2):123-6
100. Holzmann B, McIntyre BW, Weissman IL. Identification of a murine Peyer's patch-specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha. Cell 1989;56(1):37-46
101. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2013;62(8): 1122-30
102. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/ results?term=rhuMAb+%CE%B27&Search=Search
103. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/ results?term=AMG+181&Search=Search
104. Allavena R, Noy S, Andrews M, Pullen N. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010; 176(2):556-62
105. Arihiro S, Ohtani H, Suzuki M, et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int 2002;52(5-6):367-74
106. Picarella D, Hurlbut P, Rottman J, et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997;158(5):2099-106
107. Hokari R, Kato S, Matsuzaki K, et al. Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats. Clin Exp Immunol 2001;126(2): 259-65
108. Teramoto K, Miura S, Tsuzuki Y, et al. Increased lymphocyte trafficking to colonic microvessels is dependent on MAdCAM-1 and C-C chemokine mLARC/CCL20 in DSS-induced mice colitis. Clin Exp Immunol 2005;139(3):421-8
109. Goto A, Arimura Y, Shinomura Y, et al. Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflamm Bowel Dis 2006;12(8): 758-65
110. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis: a randomised study. Gut 2011;60(8): 1068-75
111. ClinicalTrials.gov. Available from: http://clinical trials.gov/ct2/ results?term=PF-00547659&Search=Search
112. Hillan KJ, Hagler KE, MacSween RN, et al. Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. Liver 1999;19(6):509-18
113. Grant AJ, Lalor PF, Hubscher SG, et al. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001;33(5): 1065-72
114. Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145(3): 521-36